- Home
- NERV vs OPP Comparison
NERV vs OPP Comparison
Compare NERV & OPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NERV | OPP |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.7M | 198.2M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | NERV | OPP |
|---|---|---|
| Price | $6.31 | $7.89 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | 98.5K | ★ 104.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 14.41% |
| EPS Growth | ★ 104.12 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,175,600.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.15 | $7.78 |
| 52 Week High | $12.46 | $8.80 |
Technical Indicators
Market Signals| Indicator | NERV | OPP |
|---|---|---|
| Relative Strength Index (RSI) | 69.16 | 47.18 |
| Support Level | $5.66 | $7.86 |
| Resistance Level | $6.69 | $8.00 |
| Average True Range (ATR) | 0.57 | 0.07 |
| MACD | 0.11 | -0.00 |
| Stochastic Oscillator | 84.44 | 26.67 |
Price Performance
Historical ComparisonAbout NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About OPP RiverNorth/DoubleLine Strategic Opportunity Fund Inc.
RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.